SAVARA INC (SVRA)
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business